The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Joshua J SolomonSonye K DanoffHilary J GoldbergFelix WoodheadMartin KolbDaniel C ChambersDonna DiFrancoCathy SpinoShana Haynes-HarpShelley HurwitzElizabeth B PetersPaul F DellaripaIvan O Rosasnull null

Published in: Advances in therapy (2019)

Clinicaltrials.gov, identifier NCT02808871.

Keyphrases

interstitial lung disease
clinical trial
idiopathic pulmonary fibrosis
double blind
rheumatoid arthritis
phase iii
phase ii
systemic sclerosis
study protocol
placebo controlled
open label
disease activity
ankylosing spondylitis